<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722421</url>
  </required_header>
  <id_info>
    <org_study_id>234-16-FB</org_study_id>
    <nct_id>NCT02722421</nct_id>
  </id_info>
  <brief_title>Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women</brief_title>
  <official_title>A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Ugandan Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Infectious Diseases Institute, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feinberg School of Medicine, Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether increasing the dose of the levonorgestrel&#xD;
      subdermal contraceptive implant will overcome a detrimental drug-drug interaction with&#xD;
      efavirenz based antiretroviral therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators research team recently demonstrated that combined use of efavirenz (EFV)&#xD;
      based antiretroviral therapy (ART), the only preferred first-line ART regimen in low and&#xD;
      middle income countries, with a levonorgestrel (LNG)-releasing implant for one year reduced&#xD;
      LNG plasma concentrations by approximately 50% compared to women not on ART. Importantly, the&#xD;
      investigators also observed three unintended pregnancies (15%) in the investigators study&#xD;
      group of women on EFV-based ART plus the LNG implant, in contrast to the &lt;1% expected failure&#xD;
      rate of the implant for women without drug interactions.&#xD;
&#xD;
      This study will determine if increasing the dose of the LNG-releasing subdermal implant&#xD;
      effectively overcomes the known pharmacokinetic interaction with EFV- based ART. LNG&#xD;
      pharmacokinetic results from the participants enrolled in this dose escalation study (n=28)&#xD;
      will be compared to HIV-infected Ugandan women on standard dose LNG without concomitant&#xD;
      EFV-based ART.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2017</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levonorgestrel plasma concentrations</measure>
    <time_frame>24-weeks after implant placement</time_frame>
    <description>We will compare levonorgestrel plasma concentrations between the participants who are receiving increased dose levonorgestrel implants plus efavirenz to historical control participants of HIV-infected Ugandan women not receiving efavirenz.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel plasma concentrations</measure>
    <time_frame>48 weeks after implant placement</time_frame>
    <description>We will compare levonorgestrel plasma concentrations between the participants who are receiving increased dose levonorgestrel implants plus efavirenz to historical control participants of HIV-infected Ugandan women not receiving efavirenz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levonorgestrel plasma concentrations</measure>
    <time_frame>Years 2-3 after implant placement</time_frame>
    <description>This arm will only be continued if safety measures are met at weeks 24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events reported by the participant or provider during the study period</measure>
    <time_frame>48 weeks after implant placement</time_frame>
    <description>Adverse events reported by participants</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in levonorgestrel concentrations between patients based on pharmacogenetic polymorphisms</measure>
    <time_frame>48 weeks after implant placement</time_frame>
    <description>Levonorgestrel PK described by pharmacogenetic polymorphisms</description>
  </other_outcome>
  <other_outcome>
    <measure>Influence of patient weight (in kg) on levonorgestrel concentrations</measure>
    <time_frame>48 weeks after implant placement</time_frame>
    <description>Levonorgestrel PK described by weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant satisfaction with the contraceptive implant reported as a likert scale based on a patient questionnaire</measure>
    <time_frame>48 weeks after implant placement</time_frame>
    <description>Patient reported satisfaction with contraceptive method</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Efavirenz group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel</intervention_name>
    <description>Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.</description>
    <arm_group_label>Efavirenz group</arm_group_label>
    <other_name>Jadelle</other_name>
    <other_name>SinoImplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Participants will receive efavirenz-based ART as part of standard of care</description>
    <arm_group_label>Efavirenz group</arm_group_label>
    <other_name>Sustiva</other_name>
    <other_name>Stocrin</other_name>
    <other_name>Atripla</other_name>
    <other_name>EFV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the participant has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          2. Participants who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
          3. Women age 18 years to 45 years&#xD;
&#xD;
          4. Diagnosed with HIV infection&#xD;
&#xD;
          5. Desiring LNG subdermal implant as a contraceptive method&#xD;
&#xD;
          6. Receiving EFV-based ART for a minimum of 3 months prior to screening&#xD;
&#xD;
          7. Must agree to have concurrent highly effective non-hormonal contraception with a&#xD;
             copper intrauterine device (IUD), if not previously medically sterilized.&#xD;
&#xD;
          8. Participants must have a negative urine pregnancy test at entry and report no&#xD;
             unprotected sex since the last menstrual period or in the last two weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HIV RNA &gt; 50 copies/mL at screening visit&#xD;
&#xD;
          2. Serum hemoglobin &lt; 10.0 g/dl&#xD;
&#xD;
          3. Elevations in serum levels of alanine transaminase (ALT) above 5 times the upper limit&#xD;
             of normal&#xD;
&#xD;
          4. Elevations in serum creatinine above 2.5 times the upper limit of normal&#xD;
&#xD;
          5. Use of drugs known to be contraindicated with LNG or EFV within 30 days of study&#xD;
             entry. Due to the dynamic nature of drug interactions related to ART, the study team&#xD;
             will review all concomitant medications at screening based on the US Department of&#xD;
             Health and Human Services drug interaction table.&#xD;
&#xD;
          6. Currently pregnant or postpartum &lt;30 days at study entry&#xD;
&#xD;
          7. Concurrent use of other hormonal contraception (Note: use of other forms of hormonal&#xD;
             contraception is permissible until time of study enrollment/insertion of LNG implant.&#xD;
             Transition from other forms of hormonal contraception to LNG subdermal implant will be&#xD;
             accommodated according to LNG product labeling)&#xD;
&#xD;
          8. For the EFV group, participants determined to be ineligible for IUD placement by the&#xD;
             World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use&#xD;
&#xD;
          9. If participation in the study puts the participant at unacceptable risk based on the&#xD;
             judgment of the study staff&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Scarsi, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Kimberly Scarsi, PharmD, MS, BCPS-ID</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>efavirenz</keyword>
  <keyword>levonorgestrel</keyword>
  <keyword>contraceptive implant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

